Table 2.
Association of Nuclear expression (H-Score) of OCT4 and also nuclear and cytoplasmic expression (H-Score) of NANOG and clinical characteristics in RCC patients.
| Expression of OCT4 | Expression of NANOG | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nuclear H-Score (N %) | *P value | Nuclear H-Score (N %) | *P value | Cytoplasmic H-Score N %) | *P value | |||||
| Patient and Tumor Charachteristics |
Total No. Cases 186 (N %) | Low (≤200) |
High
(200<) |
Low (≤160) |
High
(160<) |
Low (≤200) |
High
(200<) |
|||
| Age (y) | ||||||||||
| ≤55.2 | 87 (46.8) | 55 (30.2) | 29 (15.9) | 0.644 | 40 (23.3) | 41 (23.8) | 0.359 | 42 (23.2) | 42 (23.2) | 0.882 |
| >55.2 | 99 (53.2) | 60 (33.0) | 38 (20.9) | 52 (30.2) | 39 (22.7) | 50 (27.6) | 47 (26.0) | |||
| Sex | ||||||||||
| Male | 130 (69.9) | 54 (29.0) | 76 (40.9) | 1 | 58 (33.7) | 63 (36.6) | 503 | 67 (37.0) | 60 (33.1) | 0.516 |
| Female | 56 (30.1) | 23 (12.4) | 33 (17.7) | 21 (12.2) | 30 (17.4) | 25 (13.8) | 29 (16.0) | |||
| RCC subtypes | ||||||||||
| ccRCC | 126 (67.7) | 80 (44.0) | 43 (23.6) | 61 (35.5) | 55 (32.0) | 0.041 | 81 (44.8) | 45 (29.4) | <0.001 | |
| ChRCC | 29 (15.6) | 13 (7.1) | 15 (8.2) | 0.113 | 9 (5.2) | 18 (10.5) | 3 (1.7) | 26 (14.4) | ||
| pRCC | 31 (16.7) | 22 (12.1) | 9 (4.9) | 9 (5.2) | 20 (11.6) | 8 (4.4) | 18 (9.9) | |||
| Tumor size (cm) | ||||||||||
| <4 | 35 (18.8) | 24 (13.2) | 11 (6.0) | 19 (11.0) | 12 (7.0) | 22 (12.2) | 13 (7.2) | |||
| 04-Jul | 65 (34.9) | 43 (23.6) | 2 (11.0) | 0.182 | 31 (18.0) | 29 (16.9) | 0.748 | 28 (15.5) | 34 (18.8) | 0.307 |
| 07-Oct | 44 (23.7) | 28 (15.4) | 15 (8.2) | 23 (13.4) | 19 (11.0) | 23 (12.7) | 19 (10.5) | |||
| >10 | 42 (22.6) | 20 (11.0) | 21 (11.5) | 19 (11.0) | 20 (11.6) | 19 (10.5) | 23 (12.7) | |||
| Primary tumor (PT) Stage | ||||||||||
| I/II | 75 (40.4) | 50 (27.6) | 22 (12.2) | 0.159 | 35 (20.5) | 29 (17.0) | 0.874 | 38 (21.1) | 34 (18.9) | 0.651 |
| III/IV | 111 (59.6) | 64 (35.4) | 45 (24.9) | 56 (37.7) | 51 (29.8) | 53 (29.4) | 55 (30.6) | |||
| Histological Grade | ||||||||||
| I/II | 94 (50.5) | 65 (42.2) | 27 (17.5) | 0.169 | 49 (33.8) | 37 (25.5) | 1 | 44 (27.8) | 49 (31.0) | 1.000 |
| III/IV | 63 (33.9) | 37 (24.0) | 25 (16.2) | 33 (22.8) | 26 (17.9) | 34 (21.5) | 31 (19.6) | |||
*Significances are based on Pearson Chi-square test.
Values in bold are statistically significant.
ccRCC indicates clear cell Renal Cell Carcinoma; chRCC, chromophob Renal Cell Carcinoma and pRCC, papillary Renal Cell Carcinoma.